TY - JOUR
T1 - Mesenchymal Stem Cell Therapy in Ischemic Stroke
T2 - A Meta-analysis of Preclinical Studies
AU - Sarmah, Deepaneeta
AU - Agrawal, Vishal
AU - Rane, Pallavi
AU - Bhute, Shashikala
AU - Watanabe, Mitsuyoshi
AU - Kalia, Kiran
AU - Ghosh, Zhumur
AU - Dave, Kunjan R.
AU - Yavagal, Dileep R.
AU - Bhattacharya, Pallab
N1 - Funding Information:
The authors acknowledge Department of Science and Technology (DST), Govt. of India, for their financial support through grant (SB/YS/LS-196/ 2014), International Society for Neurochemistry (ISN) Return Home grant, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, Govt. of India, and National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar, India. The authors also thank Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA, and the Director, NIPER Ahmedabad, for providing necessary support.
Funding Information:
The authors acknowledge Department of Science and Technology (DST), Govt. of India, for their financial support through grant (SB/YS/LS-196/2014), International Society for Neurochemistry (ISN) Return Home grant, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, Govt. of India, and National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar, India. The authors also thank Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, and the Director, NIPER Ahmedabad, for providing necessary support.
Publisher Copyright:
© 2017 American Society for Clinical Pharmacology and Therapeutics
PY - 2018/6
Y1 - 2018/6
N2 - Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.
AB - Numerous preclinical studies have been carried out using mesenchymal stem cells (MSCs) therapy for ischemic stroke. The purpose of the present meta-analysis is to review the quality of preclinical studies. In all, 4,361 articles were identified, out of which 64 studies were included (excluding in vitro studies). The results were obtained across species, route, and time of administration, immunogenicity, and doses. The median quality score 4.90/10, confidence interval 95%, and large effect size were observed, which strongly supports the translation potential of MSC therapy for ischemic stroke.
UR - http://www.scopus.com/inward/record.url?scp=85038015460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038015460&partnerID=8YFLogxK
U2 - 10.1002/cpt.927
DO - 10.1002/cpt.927
M3 - Review article
C2 - 29090465
AN - SCOPUS:85038015460
VL - 103
SP - 990
EP - 998
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 6
ER -